We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viad Corp (VVI) - free report >>
Aquestive Therapeutics, Inc. (AQST) - free report >>
Harpoon Therapeutics, Inc. (HARP) - free report >>
Image: Bigstock
New Strong Buy Stocks for November 21st
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Aquestive Therapeutics, Inc. (AQST - Free Report) : This pharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 72% over the last 60 days.
Aquestive Therapeutics, Inc. Price and Consensus
Aquestive Therapeutics, Inc. price-consensus-chart | Aquestive Therapeutics, Inc. Quote
Rubicon Technologies, Inc. (RBT - Free Report) : This cloud-based waste and recycling solutions provider has seen the Zacks Consensus Estimate for its current year earnings increasing 69% over the last 60 days.
Rubicon Technologies, Inc. Price and Consensus
Rubicon Technologies, Inc. price-consensus-chart | Rubicon Technologies, Inc. Quote
Harpoon Therapeutics, Inc. (HARP - Free Report) : This immunotherapy company has seen the Zacks Consensus Estimate for its current year earnings increasing 64.2% over the last 60 days.
Harpoon Therapeutics, Inc. Price and Consensus
Harpoon Therapeutics, Inc. price-consensus-chart | Harpoon Therapeutics, Inc. Quote
Viad Corp (VVI - Free Report) : This leisure travel and events experience company has seen the Zacks Consensus Estimate for its current year earnings increasing 140% over the last 60 days.
Viad Corp Price and Consensus
Viad Corp price-consensus-chart | Viad Corp Quote
Avalo Therapeutics, Inc. (AVTX - Free Report) : This biotechnology company has seen the Zacks Consensus Estimate for its current year earnings increasing 90.3% over the last 60 days.
Avalo Therapeutics, Inc. Price and Consensus
Avalo Therapeutics, Inc. price-consensus-chart | Avalo Therapeutics, Inc. Quote
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.